116 related articles for article (PubMed ID: 35266103)
21. Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis.
Hobart J; Cano S; Baron R; Thompson A; Schwid S; Zajicek J; Andrich D
Mult Scler; 2013 Nov; 19(13):1773-83. PubMed ID: 23574800
[TBL] [Abstract][Full Text] [Related]
22. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
23. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities.
Chataway J; Murphy N; Khurana V; Schofield H; Findlay J; Adlard N
Curr Med Res Opin; 2021 Jun; 37(6):995-1004. PubMed ID: 33733976
[No Abstract] [Full Text] [Related]
24. Evaluation of the Psychometric Properties of the Revised Piper Fatigue Scale in Patients with Multiple Sclerosis.
Berardi A; Graziosi G; Ferrazzano G; Casagrande Conti L; Grasso MG; Tramontano M; Conte A; Galeoto G
Healthcare (Basel); 2022 May; 10(6):. PubMed ID: 35742037
[TBL] [Abstract][Full Text] [Related]
25. Interventions for fatigue and weight loss in adults with advanced progressive illness.
Payne C; Wiffen PJ; Martin S
Cochrane Database Syst Rev; 2012 Jan; 1():CD008427. PubMed ID: 22258985
[TBL] [Abstract][Full Text] [Related]
26. High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate.
Doesburg D; Vennegoor A; Uitdehaag BMJ; van Oosten BW
Mult Scler Relat Disord; 2019 Jun; 31():32-37. PubMed ID: 30901702
[TBL] [Abstract][Full Text] [Related]
27. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.
Gunn H; Andrade J; Paul L; Miller L; Creanor S; Stevens K; Green C; Ewings P; Barton A; Berrow M; Vickery J; Marshall B; Zajicek J; Freeman J
Health Technol Assess; 2019 Jun; 23(27):1-166. PubMed ID: 31217069
[TBL] [Abstract][Full Text] [Related]
28. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
[TBL] [Abstract][Full Text] [Related]
29. Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches.
Mannix S; Skalicky A; Buse DC; Desai P; Sapra S; Ortmeier B; Widnell K; Hareendran A
Health Qual Life Outcomes; 2016 Oct; 14(1):143. PubMed ID: 27716228
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Fatigue Management Interventions in Reducing Severity and Impact of Fatigue in People with Progressive Multiple Sclerosis: A Systematic Review.
Rooney S; Moffat F; Wood L; Paul L
Int J MS Care; 2019; 21(1):35-46. PubMed ID: 30833871
[TBL] [Abstract][Full Text] [Related]
31. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
32. The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study.
Pappalardo A; Chisari CG; Montanari E; Pesci I; Borriello G; Pozzilli C; D'Amico E; Patti F
Mult Scler Relat Disord; 2017 Oct; 17():154-171. PubMed ID: 29055451
[TBL] [Abstract][Full Text] [Related]
33. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.
Oberdhan D; Cole JC; Krasa HB; Cheng R; Czerwiec FS; Hays RD; Chapman AB; Perrone RD
Am J Kidney Dis; 2018 Feb; 71(2):225-235. PubMed ID: 29150246
[TBL] [Abstract][Full Text] [Related]
34. Development of a preliminary conceptual model of the patient experience of chronic kidney disease: a targeted literature review and analysis.
Flythe JE; Karlsson N; Sundgren A; Cordero P; Grandinetti A; Cremisi H; Rydén A
BMC Nephrol; 2021 Jun; 22(1):233. PubMed ID: 34162354
[TBL] [Abstract][Full Text] [Related]
35. Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process.
Zhang Y; Taylor BV; Simpson S; Blizzard L; van der Mei I
Eur J Neurol; 2019 Jan; 26(1):155-161. PubMed ID: 30133059
[TBL] [Abstract][Full Text] [Related]
36. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis.
Glanz BI; Zurawski J; Casady EC; Shamah R; Weiner M; Chitnis T; Weiner HL; Healy BC
Mult Scler J Exp Transl Clin; 2021; 7(2):20552173211007523. PubMed ID: 34046184
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis.
Rooney S; Wood L; Moffat F; Paul L
Mult Scler Relat Disord; 2019 Feb; 28():276-282. PubMed ID: 30639830
[TBL] [Abstract][Full Text] [Related]
38. [Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab].
Boyko OV; Choroshilova II; Petrov SV; Melnikov MV; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):120-127. PubMed ID: 31934997
[TBL] [Abstract][Full Text] [Related]
39. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?
Bharadia T; Vandercappellen J; Chitnis T; Eelen P; Bauer B; Brichetto G; Lloyd A; Schmidt H; King M; Fitzgerald J; Hach T; Hobart J
Mult Scler J Exp Transl Clin; 2022; 8(2):20552173221105642. PubMed ID: 35755007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
